Planned phase I trial of PLX BMT for graft-versus-host disease
Latest Information Update: 04 Apr 2023
Price :
$35 *
At a glance
- Drugs PLX BMT (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Sponsors Pluri
- 13 Mar 2023 According to a Pluristem Therapeutics media release, Pluristem Therapeutics has changed its name to Pluri Inc.
- 08 Oct 2013 New trial record